Pharmacotherapy for cannabis use disorder is limited and experimental. Treatment of cannabis use disorder is largely behavioral and requires a patient-centered, multifaceted approach with a focus on patient education. However, the American Academy of Family Physicians does not support this recommendation because of the lack of evidence of benefit in screening patients for unhealthy drug use, except for opioid use disorder. Preventive Services Task Force recommends universal screening for unhealthy drug use, including cannabis, in adults 18 years and older. Current evidence supports cannabinoid use only for a limited number of conditions (chemotherapy-induced nausea and vomiting, specific pain and spasticity syndromes, and certain forms of childhood epilepsy) thus, physicians recommending cannabinoids need to weigh the potential harms vs. Cannabinoids have potential adverse drug interactions with commonly prescribed analgesic, psychotropic, and cardiovascular medications.
Cannabis can impair short-term memory, judgment, and coordination, and there is substantial evidence that it can adversely affect multiple organ systems. Cannabis and its active components, cannabinoids, have been studied for medical uses and marketed in many commercial forms. This increase is fueled by state-level legalization, decreased risk perception, and increased social acceptability. Cannabis use in the United States is increasing annually in people of all ages.
0 kommentar(er)
